Document Type : Original Article


1 Iranian Center for Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

3 Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran Breast Feeding Research Center, Tehran University of Medical Sciences, Tehran, Iran


Background: Myasthenia gravis (MG) is a chronic neuromuscular disease, which physically and mentally affects the patient’s life, with depression being one of the most important psychological complications in these patients. This study aims to investigate the prevalence of depression and its associated factors in a group of Iranian patients with MG.
Methods: This was a cross-sectional study in which consecutive patients diagnosed with MG who referred to two referral neuromuscular clinics affiliated to the Tehran University of Medical Sciences, Tehran, Iran, were evaluated for eligibility. Patients with a previously known psychiatric disorder and those with a family history of mental disorders were excluded. Eligible patients were interviewed and screened for depression through the administration of the Hamilton Depression Rating Scale (HDRS) and the Iranian version of Beck Depression Inventory-II (BDI-II).
Results: A total of 62 patients participated in this study. The total prevalence of depression according to the HDRS and BDI-II scores was 64.5% and 53.2%, respectively. The mild depression was the most frequent level of depression based on the HDRS (33.9%) and BDI-II (22.6%) scores. None of the variables, including age, sex, duration of the disease, and dosages of prednisolone, pyridostigmine, and azathioprine, were correlated with the severity of depression. The number of academic years was the only variable associated with the lower HDRS score (P = 0.037).
Conclusion: Based on the current findings, depression was common among Iranian patients with MG. The severity of depressive symptoms was unrelated to age, sex, marital status, duration of the disease, the daily dosage of medications, and thymectomy status. Further investigations are needed to reveal the exact burden of depression in patients with MG and address the importance of preventive interventions for improving the quality of life (QOL) in these patients.


Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010; 10: 46.
     (2)   Kaltsatou A, Fotiou D, Tsiptsios D, Orologas A. Cognitive impairment as a central cholinergic deficit in patients with Myasthenia Gravis. BBA Clin 2015; 3: 299-303.
     (3)   Katon W. The impact of major depression on chronic medical illness. Gen Hosp Psychiatry 1996; 18(4): 215-9.
     (4)   Basta IZ, Pekmezovic TD, Peric SZ, Kisic-Tepavcevic DB, Rakocevic-Stojanovic VM, Stevic ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci 2012; 33(6): 1375-81.
     (5)   Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, et al. Factors associated with quality of life of people with Myasthenia Gravis. PLoS One 2018; 13(11): e0206754.
     (6)   Stankovic M, Peric S, Stojiljkovic TO, Stankovic T, Nikolic A, Lavrnic D, et al. Quality of life in patients with MuSK positive myasthenia gravis. Acta Neurol Belg 2018; 118(3): 423-7.
     (7)   Yang Y, Zhang M, Guo J, Ma S, Fan L, Wang X, et al. Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci 2016; 126(5): 455-62.
     (8)   Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988; 77(4): 443-5.
     (9)   Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001; 22(5): 363-9.
    (10)   Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schroder R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010; 257(9): 1473-81.
    (11)   HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
    (12)   Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian-language version of the Beck Depression Inventory--Second edition: BDI-II-PERSIAN. Depress Anxiety 2005; 21(4): 185-92.
    (13)   Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, et al. Factors associated with depressive state in patients with myasthenia gravis: A multicentre cross-sectional study. BMJ Open 2011; 1(2): e000313.
    (14)   Freeman C, Lewis I, Heckmann J. Neuropsychiatric symptoms in patients with thymoma-associated and non-thymoma myasthenia gravis. S Afr J Psychiatr 2014; 20: 4.
    (15)   Fisher J, Parkinson K, Kothari MJ. Self-reported depressive symptoms in Myasthenia Gravis. J Clin Neuromuscul Dis 2003; 4(3): 105-8.
    (16)   Aysal F, Karamustafalioglu O, Ozcelik B, Yilmaz M, Karamustafalioglu N, Yumrukcal H, et al. The relationship of symptoms of anxiety and depression with disease severity and treatment modality in Myasthenia Gravis: A cross-sectional study. Noro Psikiyatr Ars 2013; 50(4): 295-300.
    (17)   Montazeri A, Mousavi SJ, Omidvari S, Tavousi M, Hashemi A, Rostami T. Depression in Iran: A systematic review of the literature (2000-2010). Payesh 2013; 12(6): 567-94. [In Persian].
    (18)   Modabernia MJ, Tehrani HS, Fallahi M, Shirazi M, Modabbernia AH. Prevalence of depressive disorders in Rasht, Iran: A community based study. Clin Pract Epidemiol Ment Health 2008; 4: 20.